Blood tests could make kidney cancer drugs safer and more effective
NCT ID NCT04659343
First seen May 05, 2026 · Last updated May 05, 2026
Summary
This study watches how much of the cancer drug stays in the blood of people with advanced kidney cancer. The goal is to learn if adjusting doses based on drug levels can improve how well the treatment works and reduce side effects. Researchers will also look at genetics and gut bacteria to understand why some patients respond better than others. About 200 adults in Denmark who are already on treatment for metastatic kidney cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Oncology, Aarhus University Hospital
RECRUITINGAarhus, Danmark, 8200, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.